Liver DysfunctionPhase 1NCT02005744
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
A Phase 1 study testing CKD-501 in people with Liver Dysfunction, run by Chong Kun Dang Pharmaceutical at 1 site in South Korea.
Trial summary
The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function. Read more about this study
- Who is it for?
- Ages 19 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Liver Dysfunction
- What is being tested?
- CKD-501
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 26 participants
- Where
- 1 siteSouth Korea
- Study dates
- Mar 2014to Feb 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
- Inclusion Criteria
[The subjects with impaired hepatic function]
- The subjects who are 19 to 64 years old
- The subjects with stable hepatic disease and impaired hepatic function as Child-Pugh A or B
- Body Weight ≥ 55kg
- If females, Negative for pregnancy test at the screening and pre dose of Day 1
- The subjects who agreed with performing contraception during the study
- The subjects who agreed with written informed consent
[The subjects with normal hepatic function]
- The subjects who are 19 to 64 years old
- The subjects who are matched impaired hepatic function by gender, age(± 5years) and body weight(± 10kg)
- If females, Negative for pregnancy test at the screening and pre dose of Day 1
- The subjects who agreed with performing contraception during the study
- The subjects who agreed with written informed consent
- exclusion criteria
[The subjects with impaired hepatic function]
- The subjects with impaired hepatic function as Child-Pugh C
- The subjects had a portosystemic shunt surgery
- The subjects had a liver transplantation or unsuitable for the study by the investigator's judgement(for examples, hepatic encephalopathy grade 3 or 4, stroke, heart failure, cancer etc.) but The subject is eligible to participate if had not chemotherapy or radiofrequency ablation therapy within 6months)
- The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
- The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1
- Positive for anti-HIV Ab or venereal disease research laboratory etc.
[The subjects with normal hepatic function]
- The subjects with liver disease or abnormal Laboratory test(Asparate transaminase >1.25 fold of upper normal limit, Alanine transaminase>1.25 fold of upper normal limit, Total bilirubin >1.5 fold of upper normal limit)
- The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
- Estimated Glomerular filtration rate < 60 mL/min/1.73m2 by Modification of Diet in Renal Disease formula
- Positive for HBsAg, anti-Hepatitis C virus Ab, anti-HIV Ab or venereal disease research laboratory
- The subjects with high blood pressure or low blood pressure(systolic blood pressure >150mmHg or <100mmHg, diastolic blood pressure>90mmHg or <60mmHg)
- The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1 etc.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function
The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.
Read the detailed description
A Phase 1, Non-randomized, Open, Parallel-Group study.
- Conditions
- Liver Dysfunction
- Being tested
- CKD-501
- Keywords
- CKD-501
- Medical subject headings
- Liver Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CKD-501Drug
Also called Lobeglitazone
CKD-501 0.5mg, PO(per oral), once
| Study group | Role | What they receive |
|---|---|---|
| Child Pugh A | Experimental | CKD-501 will be administered to patients who are included Child Pugh A Receives: Drug: CKD-501 |
| Child Pugh B | Experimental | CKD-501 will be administered to patients who are included Child Pugh B Receives: Drug: CKD-501 |
| Subject who are matched Child Pugh A | Experimental | CKD-501 will be administered to the Subjects who are matched Child Pugh A Receives: Drug: CKD-501 |
| Subject who are matched Child Pugh B | Experimental | CKD-501 will be administered to the subjects who are matched Child Pugh B Receives: Drug: CKD-501 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Area Under the Concentration(last) and Cmax of CKD-501
Sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48
Measured: 0 to 48 hours
Secondary outcomes (4)
Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite
Sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48
Measured: 0 to 48 hours
Fraction Unbound of CKD-501 and its metabolite
sampling timepoint(hours)
: 1, 8
Measured: 1 and 8 hours
Area Under the Concentration(last) and Cmax of the metabolite
sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48
Measured: o to 48 hours
Metabolic ratio(metabolite/CKD-501)
sampling timepoint(hours)
: 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48
Measured: 0 to 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2013 (estimated)
- Study startMar 2014
- Primary completionFeb 2016
- Study completionFeb 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver DysfunctionStudies of the same condition, open and under way.
- More trials run by Chong Kun Dang PharmaceuticalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 26 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Min Soo Park, Ph.D. M.D, Principal investigator, Severance Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02005744
- Sponsor's protocol ID
- 19HI13018
- Status last verified
- May 2014
- First submitted
- 4 Dec 2013
- Last updated
- 4 Jul 2016
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function
- ClinicalTrials.gov ID
- NCT02005744
- Acronym / sponsor ID
- 19HI13018
- Conditions
- Liver Dysfunction
- Keywords
- CKD-501
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 26 participants (actual)
- Lead sponsor
- Chong Kun Dang PharmaceuticalIndustry (pharma, biotech, devices)
- Study start
- Mar 2014
- Primary completion
- Feb 2016 (actual)
- Study completion
- Feb 2016 (actual)
- First posted
- 9 Dec 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.
Detailed description
A Phase 1, Non-randomized, Open, Parallel-Group study.
Study design
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Child Pugh A | Experimental | Drug: CKD-501CKD-501 will be administered to patients who are included Child Pugh A |
| Child Pugh B | Experimental | Drug: CKD-501CKD-501 will be administered to patients who are included Child Pugh B |
| Subject who are matched Child Pugh A | Experimental | Drug: CKD-501CKD-501 will be administered to the Subjects who are matched Child Pugh A |
| Subject who are matched Child Pugh B | Experimental | Drug: CKD-501CKD-501 will be administered to the subjects who are matched Child Pugh B |
Who may qualify
- Ages
- 19 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CKD-501Also: LobeglitazoneCKD-501 0.5mg, PO(per oral), once | Drug | Child Pugh A, Child Pugh B, Subject who are matched Child Pugh A, Subject who are matched Child Pugh B |
Primary outcome
Area Under the Concentration(last) and Cmax of CKD-501
Time frame: 0 to 48 hours
Sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48
4 secondary outcomes
Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite
Time frame: 0 to 48 hours
Fraction Unbound of CKD-501 and its metabolite
Time frame: 1 and 8 hours
Area Under the Concentration(last) and Cmax of the metabolite
Time frame: o to 48 hours
Metabolic ratio(metabolite/CKD-501)
Time frame: 0 to 48 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jul 2016.
Related trials for Liver Dysfunction
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Not yet recruiting
New Biomarkers for Organ Viability Assessment During Hypothermic Machine Perfusion in Liver Transplantation: the Role of Extemporaneous Histological Examination.
Liver Transplantation (LT), Early Allograft Dysfunction
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Min Soo Park, Ph.D. M.D principal investigator
Severance Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing CKD-501 in people with Liver Dysfunction, run by Chong Kun Dang Pharmaceutical at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Area Under the Concentration(last) and Cmax of CKD-501 (time frame: 0 to 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jul 2016.